C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial
ConclusionsEculizumab blunted terminal complement activation in all patients with immune complex–mediated MPGN or C3 glomerulonephritis and nephrotic syndrome, but persistently reduced proteinuria in just a subgroup.Trial RegistrationRegistered in the EU Clinical Trials Register with study no. 2013-003826-10.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Clinical Trials | Glomerulonephritis | Italy Health | Nephrotic Syndrome | Proteinuria | Study | Urology & Nephrology